Rubbing my ball, page-462

I don't know why anyone is hung up on the idea of a special dividend now when we have several potential treatments to get through trials. A partner for her-vaxx to pay for phase 3 trial and take to US market if successful would be great. If that came with extra funds then surely we would use that to fund the trials for our other indications, rather than another cap raise a year or two down the line. I also wouldn't be adverse to IMU acquiring further IP, the team clearly have an eye for it.

No point cashing in for a pittance now if it hampers long term flexibility for the company later. Dividends can come once we're actually generating sales/royalties.